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In vitro proliferation of leukemic cells purified from 10 
cases of acute myeloblastic leukemia (AML) was analyzed in 
basal conditions or in the presence of exogenous recombinant 
(r) Interleukin (IL) I. In parallel, blasts from 5 of these pa- 
tients were studied for granulocyte-macrophage colony- 
stimulating factor (GM-CSF) or granulocyte-CSF (G-CSF) 
mRNA. 11-1 augmented the spontaneous AML cell prolifera- 
tion in all cases and induced de novo expression or increased 
amounts of GM-CSF and/or G-CSF transcripts in 4 of the 5 
cases evaluated. IL- I -induced AML cell proliferation was mod- 
ulated by neutralizing anti-GM-CSF or anti-G-CSF antibodies 
in those cases in which CSF mRNAs were induced or in- 
creased by exogenous cytokine. In the same cases, biosyn- 
thetic labelling and immunoprecipitation studies using mono- 
specific anti-GM-CSF antibodies showed that IL-l also in- 
creased the levels of GM-CSF protein synthesis. Addition of 
neutralizing anti-lL- I antibodies to AML cell cultures com- 
pletely abolished ongoing GM-CSF synthesis, suggesting that 
endogenous IL- I is needed to maintain autocrine production 
of CSFs. The effects of rlL-2 were investigated in a larger 
series of 21 patients. The cytokine reduced spontaneous AML 
cell proliferation in 8 cases. It caused complete disappearance 
of GM-CSF mRNA in I case, and marked reduction of G-CSF 
mRNA in 2 cases. Increased AML cell proliferation was ob- 
served in 2 of 21 cases. These findings suggest that expression 
of CSF genes and cell proliferation in AML are under the 
control of different cytokines acting in autocrine or paracrine 
fashion. 
Normal hematopoiesis is regulated through discrete steps of 
differentiation, which require the action of growth factors, and 
particularly a group of glycoproteins known as colony- 
stimulating factors (CSFs) (Clark and Kamen, 1987). Growth 
of normal and leukemic blast progenitors is also influenced by 
the activity of a growing number of other molecules. In par- 
ticular, cytokines, originally thought to mainly regulate im- 
mune functions or inflammation, such as ?-Interferon (y-IFN), 
tumor necrosis factor-a (TNF-a), Interleukin (1L)-I , IL-4 and 
IL-6, have been shown to play a critical role in hematopoiesis 
(Metcalf, 1989; Trinchieri et al., 1987). Indeed, these proteins 
are linked in a complex network, whereby they influence each 
other's function, in terms of gene expression, protein synthesis 
and secretion, and interaction with surface receptors. Further 
complexity is added by the observation that CSFs and IL-1 
genes are constitutively expressed in acute myeloblastic leuke- 
mia (AML) cells, with production and secretion of the respec- 
tive mature proteins (Young and Griffin, 1986; Young et al., 
1987; Rambaldi et al., 1988; Griffin et al., 1987; Furukawa et 
al., 1987; Cozzolino et al., 1988, 1989). It is possible that the 
factors are linked by regulatory connections within the leuke- 
mic cell. Surface expression of IL-2 receptor light chain has 
been reported in AML (Hermann et al., 1985; Rambaldi et al., 
1987). Although functional consequences of leukemic cell in- 
teractions with the cytokine have not been defined, studies on 
normal monocytes have demonstrated an influence on some 
cellular functions (Malkovsky et al., 1987). Dissection of such 
interactions appears important for a thorough understanding of 
normal as well as of leukemic hematopoiesis. 
We therefore decided to investigate the effects of 2 cyto- 
kines, IL-1 and IL-2, on AML cell proliferation and on gene 
expression and protein synthesis of GM-CSF and G-CSF. 
MATERIAL AND METHODS 
Leukemic cells 
Leukemic cells were obtained, after informed consent, at 
diagnosis from peripheral blood of 21 randomly selected pa- 
tients and the mononuclear fraction was isolated by sedimen- 
tation on Ficoll-Hypaque density gradients. Samples were 
cryopreserved in 10% DMSO in the vapor phase of liquid 
nitrogen until use. The diagnosis of AML was established by 
morphology, cytochemistry and surface marker analysis using 
a panel of anti-myeloid monoclonal antibodies (MAbs) (Griffin 
et al., 1981). The patients were classified according to the 
FAB scheme (Bennett et al., 1976) as follows: 4 patients with 
MI AML, 6 with M2, 6 with M4, and 5 with M5. In all 
experiments, leukemic cells were depleted of T cells by roset- 
ting with neuraminidase-treated sheep red blood cells and de- 
pleted of monocytes by plastic adherence at 37" C. The per- 
centage of cells expressing the p55 subunit of IL-2 receptor 
was assessed by flow cytometry of cells stained with anti- 
CD25 MAbs (anti-Tac) (Cozzolino et al., 1987). 
Recombinant cytokines and antibodies 
Purified human recombinant (hr) IL-1 a and p (specific 
activity of both: 1.3 X lo7 half maximal units/mg in the thy- 
mocyte co-stimulation assay) and hrIL-2 (specific activity: 
1.3 x lo7 units/mg in the CTLL-2 proliferation assay) were 
obtained through the courtesy of Dr. A. Shaw (Glaxo, Geneva, 
Switzerland). IgG fractions of neutralizing anti-GM-CSF, anti- 
G-CSF, anti-IL-l a and anti-IL-1 p sheep antisera, generous 
gifts from Dr. S. Poole (National Institute for Biological Stan- 
dards and Controls, Potters Bar, UK), and of pre-immune 
sheep or rabbit serum were obtained by Affi-Gel Protein A 
(Bio-Rad, Milan, Italy) affinity chromatography and used at 5 
p,g/ml final dilution for proliferation or immunoprecipitation 
studies. The latter concentration of anti-CSFs antibodies neu- 
tralized the growth-promoting activity of 250 U/ml of rGM- 
CSF or G-CSF (Genzyme, Boston, MA) on selected AML 
cells; 5 pg of anti-IL-1 a or anti-IL-1 p IgG neutralized >15 
ng of the respective cytokine, with no cross-reactivity, in the 
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thymocyte co-stimulation assay. Neutralizing rabbit anti- 
human IL-2 IgG (specific activity: 3000 neutralizing units/mg) 
were purchased from Collaborative Research (Bedford, MA) 
and used at 50 pglml final dilution. 
Leukemic cell proliferation assay 
For the cell proliferation studies, different concentrations of 
leukemic cells, from 5 X 104/ml to 2.5 X 105/ml, were incu- 
bated in RPMI 1640 medium (GIBCO, Grand Island, NY) 
supplemented with 2 mM L-glutarnine, 100 U/ml of penicillin, 
100 kg/ml streptomycin and 10% fetal calf serum (FCS, 
GIBCO) for 48 hr, in the presence or absence of the different 
cytokines and of neutralizing antibodies or control IgG. Cul- 
tures were pulsed with 0.5 pCi of 3H-thymidine (specific ac- 
tivity 25 C i / m ,  Amersham, Little Chalfont, UK) 12 hr before 
harvesting and radioactivity was determined in a liquid scin- 
tillation counter (Beckman Analytical, Milan, Italy). 
Northern blots 
Cells (5  X lo7), cultured for 12 hr in the presence or absence 
of IL-1 or IL-2, 5 ng/ml each, were lysed in 4 M guanidinium 
isothiocyanate and RNA was extracted, electrophoresed in aga- 
rose gel, and blotted (Rambaldi el al., 1988). Membranes were 
hybridized to GM-CSF and G-CSF cDNA probes (kindly pro- 
vided by Drs. s. Clark and G. Wong, Genetics Institute, Cam- 
bridge, MA) (Clark and Kanien, 1987), labelled with 
32P-dCTP by the method of Feinlberg and Vogelstein (1983). 
The UCD-MLA 144 gibbon cell line was obtained from ATCC 
(Rockville, MD) and grown in IRPMI 1640 medium supple- 
mented with 2 m L-glutamine ;and 10% fetal bovine serum; 
after stimulation with 20 ng/ml phorbol myristate acetate 
(PMA, Sigma, St. Louis, MO), RNA was isolated from this 
cell line and used as a source of GM-CSF RNA. To ascertain 
that comparable amounts of RNA were transferred, each mem- 
brane was re-hybridized to a mouse actin cDNA probe. 
Irnrnunoprecipitation studies 
Endogenous labelling and immunoprecipitation studies were 
performed as described by Cozzolino et al. (1989). Cells were 
incubated at 107/ml for 12 hr in methionine- and cysteine-free 
RPMI 1640 medium (GIBCO) supplemented with 5% dialyzed 
FCS, 5 X 10 -’ M 2-mercaptoethanol (2-ME), 35S-methionine 
and ’?S-cysteine (specific activity: 800 Ci/mmol and 600 Ci/ 
mM, respectively, NEN-Du Pont, Florence, Italy), 100 pCi/ml 
each, in the presence or absence of rIL-1 ci or p, 5 nglml. In 
selected experiments, cells were cultured with IgG fraction of 
neutralizing anti-IL-1 a and anti-IL-1 p antisera (5 pg/ml 
each), or of control sheep serum. Cells were then centrifuged, 
washed and lysed in PBS with 0.5% Nonidet P-40. Samples of 
supernatants and of cell lysates were immunoprecipitated with 
5 pg of IgG fraction of anti-GM-CSF or of pre-immune sheep 
IgG as control, followed by 50 pl of Protein A Sepharose 
CL4B (Pharmacia, Uppsala, Sweden). Immunoprecipitates 
were extensively washed, eluted by boiling in Laemmli stack- 
ing buffer containing 2% (v/v) SDS and 5% 2-ME, and sub- 
jected to SDS-polyacrylamide (1 2%) gel electrophoresis. Gels 
were then dried and autoradiographed with intensifying 
screens. 
RESUL,TS 
Effects of IL-1 and IL-2 on AML proliferation 
We have previously shown that rIL-1 ci or p induce in vitro 
growth of AML cells (Cozzolino et al., 1989). To further 
investigate this point, the effect of IL-1 was studied in a pro- 
liferation assay (3H-thymidine incorporation), using different 
concentrations of blast cells plated with the recombinant factor 
for 48 hr, with or without neutralizing anti-CSF antibodies. 
Table I summarizes the results obtained with cells from 10 
TABLE I - EFFECT OF IL-1 ON AML CELL PROLIFERATION 
’H-TdR incorporation (cpm) in the presence of’ 
Case 
IL-1 + IL-1 + 
anri-GM-CSF’.’ anti-G-CSF2.3 Medium IL-12 
1 18,235 45,645 20,438 27,848 
2 4,370 21,438 13,456 15,437 
3 2,850 8,545 9,043 ND 
4 10,368 51,543 18,775 21,348 
5 2,235 30,456 4,004 32,043 
6 764 7,843 7,935 ND 
7 2,491 5,432 5,177 4,988 
8 4,095 18,473 9,543 13,334 
9 323 2,445 657 ND 
10 723 6,148 6,044 5,980 
‘Leukemic cells were cultured at 2 .5  X 105/ml (cases 1 ,  3,  4, 5) .  at 1 .2 X IOs/ml 
(cases 2. 6,  8, lo), or at 5 x 104/ml (cases 5. 7) for 48 hr in the presence or absence 
of the indicated reagents. ’H-TdR was added during the last 12 hr of  culture. Results 
Te expressed as mean cpm of triplicate cultures. SD was consistently <lo%. 
--hrIL-la or p were used at the final concentration of 5 ng/~nI.-~Neutralizing sheep 
anti-GM-CSF and anti-G-CSF antibodies were used at the final concentration of 5 
&ml. Pre-immune sheep IgG, used as control at the concentration of 5 pgiml, was 
ineffective in the assay. 
AML patients, where IL- 1 induced an increased proliferation 
rate at the appropriate cell density in culture (Cozzolino et al., 
1989). The addition of neutralizing antibodies directed against 
GM-CSF was followed by a significant, though not complete, 
reduction of IL-1 -induced AML proliferation in 6 cases. When 
tested, neutralizing anti-G-CSF antibodies showed a pattern of 
activity parallel to that of anti-GM-CSF antibodies. 
Based on the observation that myeloid leukemic cells, as 
well as activated normal monocytes, can express the p55 sub- 
unit of the IL-2 receptor on their surface (Herrmann et a l . ,  
1985; Rambaldi et al., 1987), we tested, in a larger series of 
cases, the possibility that IL-2 might also work on AML as a 
growth-regulating signal. When IL-2 was added to the culture 
medium, we observed in 8 of 21 cases variable degrees of 
inhibition of AML proliferation, ranging from 52 to a maxi- 
mum of 83% (Table 11). In 2 cases, however, definite induction 
of growth was recorded. The addition of saturating amounts of 
neutralizing antibodies directed against human IL-2 was able to 
prevent the activity of AML cell proliferation. Phenotypic 
analysis, performed on 13 of these cases, showed a correspon- 
dence between the response to IL-2 and the expression of the 
p55 subunit of the IL-2 receptor complex (Table 11). 
Effects of IL-I and IL-2 on GM-CSF and G-CSF 
gene expression 
Because CSFs have been reported to act as autocrine stim- 
ulators of AML blast proliferation (Young and Griffin, 1986; 
Young et al., 1987; Rambaldi et al., 1988; Griffin et al., 
1987), we tested the possibility that the effects of IL-1 and IL-2 
on leukemic growth could be exerted, at least in part, through 
interference with expression of CSF genes, as suggested by the 
above experiments with IL-1 and anti-GM-CSF or anti-G-CSF 
antibodies. Upon culture in the presence of medium alone or 
with rIL-1 p, leukemic-cell-derived mRNA was examined for 
GM-CSF and G-CSF gene expression (Fig. la, b).  In one case 
(5) leukemic cells cultured in medium alone did not express 
any of the growth factor genes studied, but the addition of 
rIL-1 p was followed by the accumulation of GM-CSF mRNA 
within the blasts. In 3 cases (1,2 and 4) expression of GM-CSF 
and G-CSF genes was detectable upon culture in medium 
alone. In all of these the exposure of leukemic blasts to IL-1 
was followed by increased levels of GM-CSF transcription, 
whereas definite augmentation of G-CSF mRNA was induced 
only in blasts from case 1. In one more case (3), no GM-CSF 
or G-CSF transcripts were detected under control conditions, 
as well as after addition of IL-1. Remarkably, in single cases 
a close correspondence was observed between levels of CSF 
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TABLE I1 - EFFECT OF IL-2 ON AML CELL PROLIFERATION 
3H-TdR incorporation (cpm) in the presence of' 
finding which further supports the hypothesis that IL-I and 
CSFs are functionally linked within the malignant cell. 
Case 
number' rIL-z2 + 
anti-1~-2~ Medium r1~-2' 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
18,235 
6,556 
2,850 
10,368 
2,235 
1,252 
8,538 
12,659 
2,675 
1,348 
1;852 
2,491 
564 
517 
22,238 
1,160 
12.595 
720 
1,314 
47,192 
9.747 
5,659 
3,147 
3,120 
9,675 
703 
1,374 
8,525 
6,102 
2,450 
1.426 
17;353 
2,626 
87 1 
630 
14,558 
202 
33.189 
690 
457 
35,190 
10.449 
18,043 
5,740 
ND 
11,243 
1,772 
1,278 
ND 
11,964 
ND 
ND 
2,657 
ND 
ND 
ND 
23,467 
1,122 
14,236 
ND 
1,103 
46,883 
ND 
'Leukemic cells were cultured at 2.5 X lO'iml for 48 hr. 'H-TdR was added 
during the last 12 hr of culture. Results are expressed as mean cym of triplicate 
cultures. SD was consistently <lO%.-*rIL-2 was used at 5 ngim1.--Rabbit neutral- 
izing anti-lL-2 antibodies were used at the final concentration of 50 pgiml. Pre- 
immune rabbit IgC, used as control at the same concentration, was ineffective in the 
a~say.-~Cases 1 , 2 , 5 ,  8, 11, 15 and 20 had >80% circulating CD25+ cells; cases 3,  
4, 6 ,  7. 9 and 10 had <lo% CD25+ cells. ND: not determined. 
gene expression in response to IL-1 and modulation of IL- 
1-induced proliferation by anti-CSF antibodies (Fig. 1, Ta- 
ble I). 
By contrast, exposure of leukemic blasts from case 1 to IL-2 
was followed by complete suppression of high levels of GM- 
CSF mRNA constitutively present under control conditions 
(Fig. la). While no significant modulation of GM-CSF tran- 
scription was found in cases 2 and 4, the inhibitory effect of 
IL-2 on G-CSF gene expression was observed in cases 1 and 2 
(Fig. lb ) .  As shown in Table I, in these latter cases rIL-2 
caused a reduction in spontaneous leukemic cell proliferation. 
However, this occurred also in case 5, where no constitutive 
expression of CSF genes was detected. 
Effects of rIL-1 and of anti-IL-1 antibodies on 
GM-CSF production 
In order to verify whether leukemic cells were indeed syn- 
thesizing GM-CSF protein, control and IL- 1-treated blasts, 
metabolically labelled with ?S-methionine and 35S-cysteine, 
were tested for expression of the protein using polyclonal anti- 
GM-CSF antibodies. As shown in Figure 2, the 25-kDa poly- 
peptide was immunoprecipitated from leukemic cell lysates of 
case 2, with significantly higher levels of protein in IL- 
1-treated blasts. No GM-CSF was detected in culture superna- 
tants. The same pattern was observed in cases l and 4 (not 
shown). 
We have previously shown that IL-1 is invariably produced 
by AML cells, and that neutralizing anti-IL-1 antibodies affect 
leukemic cell proliferation (Cozzolino et al., 1989). To ascer- 
tain whether endogenous IL- 1 sustains autocrine GM-CSF pro- 
duction, at least in those cases with constitutive synthesis, in 
another series of experiments, AML cells from case 1 were 
metabolically labelled upon culture with neutralizing anti-IL-1 
a and anti-IL-1 (3 antibodies, and cell lysates were studied as 
above. Figure 3 shows that incubation with anti-IL-1 antibod- 
ies, in amounts sufficient to abrogate leukemic cell prolifera- 
tion, completely abolished GM-CSF synthesis in culture, a 
DISCUSSION 
Proliferation of human leukemic myeloblasts requires the 
presence of CSFs (Clark and Kamen, 1987; Metcalf, 1989; 
Trinchieri et al., 1987). Evidence has been provided on dis- 
regulated CSF gene expression which, in some cases of AML, 
could sustain autocrine stimulation (Vellenga and Griffin, 
1987). However, other cases of AML show no apparent CSF 
gene activation, and a more sophisticated network of humoral 
interactions between endothelial cells, fibroblasts and leukemic 
cells could be responsible for growth factor supply. Part of 
this interaction could be mediated by biologically active IL- 1 
which is secreted by the majority of AMLs and is a potent 
stimulator of CSF secretion by fibroblasts and endothelial cells 
(Griffin et al., 1987; Seelentag et al., 1989; Sieff et al., 1987). 
On the other hand, a direct IL-1-mediated autocrine stimulation 
pathway in AML has also been proposed (Cozzolino er al., 
1989). 
In the present work we show data suggesting that IL-1 can 
stimulate AML growth in vitro through its ability to regulate 
gene expression and protein synthesis of GM-CSF and G-CSF. 
As already seen (Cozzolino et al., 1989), IL-1 was able to 
induce leukemic cell proliferation, as determined by 3H-thy- 
midine incorporation; such growth factor activity was inhibited 
partially, though not completely, by the addition to the culture 
media of anti-GM-CSF or anti-G-CSF polyclonal antibodies, 
thus supporting the hypothesis that at least part of the effect is 
mediated by these CSFs. Using Northern blot analysis we have 
shown that, when exposed to IL-1, GM-CSF or G-CSF tran- 
scription could be induced or up-regulated in the majority of 
the AMLs cases studied. Under the same culture conditions, 
this finding was confirmed by the immunoprecipitation of in- 
creased levels of GM-CSF protein. These results confirm and 
extend those of Delwel et al. (1989). Abrogation of IL- 
1 -induced proliferation by anti-GM-CSF antibodies was not 
complete. This finding suggests the induction of growth factors 
other than those tested. However, this observation, together 
with the detection in our cases of GM-CSF in cell lysates but 
not in culture supernatants, could also be explained considering 
that the growth factor delivers at least part of its proliferative 
signal within intracellular compartments, as demonstrated in 
leukemic cell lines transfected with modified IL-3-coding 
genes (Dunbar et al., 1989). The notion that IL-1 can subserve 
autocrine functions in AML raises the question of whether the 
endogenous cytokine is directly exerting its growth-promoting 
activity or whether it regulates the levels of other autocrine 
factors, possibly sustaining neoplastic growth. The observation 
that rIL- 1 increases endogenous CSF levels, while anti-IL-1 
antibodies abrogate their synthesis, favors the latter hypothe- 
sis, that of a hierarchical connection linking the factors. How- 
ever, it is conceivable that expression of other genes, such as 
IL-3 or IL-6, is up-regulated by IL-1, as suggested by cyto- 
kine-induced proliferation in those cases in which no GM-CSF 
or G-CSF transcripts were detected. The question bears rele- 
vance for possible therapeutic strategies. 
AML cells may express the p55 sub-unit of the IL-2 receptor 
(Herrmann et al., 1985; Rambaldi et al., 1987). Our results 
show that incubation with rIL-2 induces a decrease in autono- 
mous cell proliferation in 8 of 21 AML cases. In 2 cases, 
characterized by high levels of Tac + blasts, autonomous 
growth in vitro, and constitutive expression of the GM-CSF 
and/or G-CSF genes, incubation with rIL-2 caused a reduction 
in the proliferation rate and a decrease or even abrogation of 
CSF gene expression. In one case with no expression of either 
G-CSF or GM-CSF, IL-2 had no effect on blast proliferation; 
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FIGURE 1 - Effects of IL-1 and 1L.-2 on GM-CSF (a) or G-CSF (b) gene expression. Northern blot of mRNA extracted from 5 X lo7 cells 
of cases 1-5, cultured for 12 hr with or without 5 nglml of either cytokine. The amount of mRNA loaded into each lane was checked by 
rehybridizing the membrane to a mouse actin cDNA probe. 
in another case with similar features the cytokine profoundly 
reduced leukemic cell growth. This might be explained by 
interference with the expression of other growth factors or of 
surface receptors. Our data are consistent with the reported 
maturation- rather than growth-promoting effects of IL-2 on 
normal monocytes. However, in 2 cases, induction of prolif- 
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FIGURE 2 - Effect of IL-1 on GM-CSF protein synthesis. Cells 
from case 2 were metabolically labelled in the absence (lanes 1 and 2) 
or presence (lanes 3 and 4) of 5 ng/ml of rIL-1 p, and supernatants 
(lanes 1 and 3) and cell lysates (lanes 2 and 4) were immunoprecipi- 
tated with anti-GM-CSF polyclonal antibodies, run in SDS-poly- 
acrylamide gel electrophoresis and autoradiographed. 
eration has been noted, as also observed, although with a 
higher frequency, by Carron and Cawley (1989). The func- 
tional heterogeneity of IL-2 activity probably reflects its im- 
pingement on undefined, subtle differences in the molecular 
pathways governing AML cell proliferation and differentia- 
tion. For example, it is possible that in certain AML cases IL-2 
induces IL-1 secretion, as reported for normal monocytes (Her- 
mann et al., 1989), thus boosting cell growth. Overall, these 
findings suggest that IL-2 may also be involved in the mech- 
anisms controlling proliferation of normal myeloid progenitor 
cells. Finally, the observation that the cytokine per se affects 
malignant cell proliferation, albeit in a minority of cases, could 
also have a clinical relevance, in the light of ongoing thera- 
peutic trials using lymphokine-activated killer (LAK) cells plus 
rIL-2. 
FIGURE 3 - Effect of anti-IL-1 antibodies on GM-CSF protein syn- 
thesis. Cells from case 1 were metabolically labelled upon culture in 
medium alone (lane I ) ,  in the presence of 5 p.g/ml of neutralizing 
sheep anti-IL-l polyclonal IgG (lane 2). or of 5 p.g/ml of sheep pre- 
immune IgG (lane 3). Cell lysates were immunoprecipitated with anti- 
GM-CSF antibodies, run in SDS-polyacrylamide gel electrophoresis 
and autoradiographed. 
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